South Africa's Aspen Pharmacare is targeting the diabetes and obesity drug market as patents for these drugs expire in emerging markets. The company aims to manufacture and sell GLP-1 drugs starting in 2026. Aspen has secured a license agreement for the intellectual property associated with generic semaglutides, presenting commercial and manufacturing opportunities. The CEO believes there is a market opportunity for more affordable drugs that will drive a surge in global volumes as more patients access these treatments.